EqiTX seeks control of CRC-VT vaccine project

2 July 2006

Publically-held Australian biotechnology firm EQiTX has decided to restructure its synthetic vaccine project into a fully-owned vehicle called ImmunoTX Pty Ltd. EQiTX currently holds 42% of the equity in the company, which was formed in January 2004 by EQiTX and the Cooperative Research Centre for Vaccine Technology. The firm is negotiating with the beneficiaries of the CRC-VT, which will close on June 30, 2006, after 13 years of funding from the Australian Government.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight